ArticleCase reports in endocrinology2026
Lugol's Iodine as a Key Treatment in Transient Gestational Thyrotoxicosis: A Case Report.
Article in Case reports in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lugol's Iodine as a Key Treatment in Transient Gestational Thyrotoxicosis: A Case Report.Case reports in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Transient gestational thyrotoxicosis (TGT) occurs when human chorionic gonadotropin (hCG) directly stimulates the maternal thyroid gland during the first trimester of pregnancy. We report a case of complicated TGT in a young woman who required treatment with Lugol's solution. Case Presentation: A 29-year-old pregnant woman, at 10 weeks gestation and with no significant medical history, was referred to the endocrinology department for evaluation of hyperthyroidism. She had been experiencing persistent vomiting, anorexia, fatigue, palpitations, abdominal pain, and unintentional weight loss for 2 weeks. On examination, her heart rate was at 120 bpm, and she exhibited resting tremors, but there were no signs of exophthalmos or goiter. Laboratory results revealed a free T4 level 2.2 times above the upper limit of the normal range, with a thyroid-stimulating hormone (TSH) level of 0.01 mUI/L. Tests for thyroid receptor antibodies, thyroid peroxidase antibodies, and anti-thyroglobulin antibodies were negative. A cervical ultrasound with Doppler showed a normal-sized thyroid gland without hypervascularity or nodules, confirming the diagnosis of TGT.Additionally, liver enzyme abnormalities were observed, with ASAT elevated 4.84 times and ALAT 3.42 times the normal limit. Also, acute pancreatitis was diagnosed, as evidenced by a lipase level three times above the upper limit of normal. Given the contraindications for antithyroid drugs (ATDs) and glucocorticoids, treatment was initiated with Lugol's iodine 5% (five drops three times daily) and propranolol (60 mg/day) for 2 weeks. Symptoms of thyrotoxicosis resolved, free T4 returned to normal levels, and liver enzymes normalized. Conclusion: This case highlights the interesting role of Lugol's iodine as a short-term and effective therapeutic option in selected cases of TGT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.